AI assistant
Episurf — Board/Management Information 2017
Jan 18, 2017
3157_rns_2017-01-18_45cf923a-ee7f-4866-9f71-4e74813dfc2f.pdf
Board/Management Information
Open in viewerOpens in your device viewer
Company Announcement January 18, 2017
Episurf Medical AB is expanding its Clinical Advisory Board
Episurf Medical AB is expanding its Clinical Advisory Board with the addition of Dr Adam Mitchell. Dr Mitchell is a radiologist whose practice is focused on the treatment of high calibre athletes at the sports medicine focused Fortius Clinic in London. His expertise in radiological technology being utilised to help young patients, will complement the Episurf Clinical Advisory Board and give an even broader understanding of treatment pathways for cartilage patients.
"I have had the pleasure of meeting and presenting with Dr Mitchell and his future-focus and attention to detail are skills we are looking forward to tapping into", says Dr Leif Ryd, Chairman of Episurf's Clinical Advisory Board. "We are very excited that Dr Mitchell has agreed to join our advisory team and we look forward to working with him to aid us in positioning our technology within the area of medical imaging".
For more information, please contact: Pål Ryfors, acting CEO, Episurf Medical Tel: +46 709 62 36 69 Email: [email protected]
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above.